The clinical-stage biotech hardly made a sound during the first three months of the year
News & Analysis: AnaptysBio
Fourth-quarter progress set the biotech up with several new paths to success.
The clinical-stage biotech stock slid despite a third-quarter report that didn't contain any surprises.
The clinical-stage biotech's third-quarter report contained some important pipeline updates.
Investors received good news from the clinic for an important development-stage asset.
The biopharma announced positive top-line data from a phase 2a trial involving its lead drug candidate as a treatment for asthma.
It looks like this biotech's research and development outlay will be peanut-free from now on.
A wild week (and a wild year) continue for the clinical-stage biopharma.
Drugs in development took important steps forward, and investors can anticipate more catalysts ahead.
Analyst downgrades following recently released peanut allergy results appear to be the culprit.